These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Children versus adults: pharmacokinetic and adverse-effect differences. Anderson GD Epilepsia; 2002; 43 Suppl 3():53-9. PubMed ID: 12060006 [TBL] [Abstract][Full Text] [Related]
23. Thinking out of the box: management of valproic acid toxicity with carbapenems. Sanivarapu R; Sharma R; Akella J BMJ Case Rep; 2021 Mar; 14(3):. PubMed ID: 33692057 [TBL] [Abstract][Full Text] [Related]
24. Subchronic effects of valproic acid on gene expression profiles for lipid metabolism in mouse liver. Lee MH; Kim M; Lee BH; Kim JH; Kang KS; Kim HL; Yoon BI; Chung H; Kong G; Lee MO Toxicol Appl Pharmacol; 2008 Feb; 226(3):271-84. PubMed ID: 17963808 [TBL] [Abstract][Full Text] [Related]
29. Valproate (VPA) metabolites in various clinical conditions of probable VPA-associated hepatotoxicity. Siemes H; Nau H; Schultze K; Wittfoht W; Drews E; Penzien J; Seidel U Epilepsia; 1993; 34(2):332-46. PubMed ID: 8453944 [TBL] [Abstract][Full Text] [Related]
30. Influence of valproic acid on the expression of various acyl-CoA dehydrogenases in rats. Kibayashi M; Nagao M; Chiba S Pediatr Int; 1999 Feb; 41(1):52-60. PubMed ID: 10200137 [TBL] [Abstract][Full Text] [Related]
31. Hepatotoxicity in rat following administration of valproic acid. Sugimoto T; Woo M; Nishida N; Takeuchi T; Sakane Y; Kobayashi Y Epilepsia; 1987; 28(2):142-6. PubMed ID: 3102219 [TBL] [Abstract][Full Text] [Related]
32. Protective effects of naringin on valproic acid-induced hepatotoxicity in rats. Koroglu OF; Gunata M; Vardi N; Yildiz A; Ates B; Colak C; Tanriverdi LH; Parlakpinar H Tissue Cell; 2021 Oct; 72():101526. PubMed ID: 33756270 [TBL] [Abstract][Full Text] [Related]
34. Association of CYP2C9, CYP2A6, ACSM2A, and CPT1A gene polymorphisms with adverse effects of valproic acid in Chinese patients with epilepsy. Wang C; Wang P; Yang LP; Pan J; Yang X; Ma HY Epilepsy Res; 2017 May; 132():64-69. PubMed ID: 28315807 [TBL] [Abstract][Full Text] [Related]
35. Science review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence? Lheureux PE; Penaloza A; Zahir S; Gris M Crit Care; 2005 Oct; 9(5):431-40. PubMed ID: 16277730 [TBL] [Abstract][Full Text] [Related]
37. Association between the perturbation of bile acid homeostasis and valproic acid-induced hepatotoxicity. Chen Y; Zhou J; Xu S; Liu M; Wang M; Ma Y; Zhao M; Wang Z; Guo Y; Zhao L Biochem Pharmacol; 2019 Dec; 170():113669. PubMed ID: 31628911 [TBL] [Abstract][Full Text] [Related]
38. POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders. Saneto RP; Lee IC; Koenig MK; Bao X; Weng SW; Naviaux RK; Wong LJ Seizure; 2010 Apr; 19(3):140-6. PubMed ID: 20138553 [TBL] [Abstract][Full Text] [Related]
39. Valproic acid hepatic fatalities. III. U.S. experience since 1986. Bryant AE; Dreifuss FE Neurology; 1996 Feb; 46(2):465-9. PubMed ID: 8614514 [TBL] [Abstract][Full Text] [Related]
40. Routine laboratory monitoring for serious adverse effects of antiepileptic medications: the controversy. Wyllie E; Wyllie R Epilepsia; 1991; 32 Suppl 5():S74-9. PubMed ID: 1743173 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]